Contributions
Abstract: PB1393
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Outcomes of Acute Promyelocytic Leukemia (APML) have improved considerably with the use of targeted therapies in trials.
Aims
We aimed to study the outcomes of APML in real-word WA patients.
Methods
Retrospective, multicentre analysis of survival outcomes of patients with APML presenting to public tertiary hospitals from 2005-2019 was undertaken, median follow-up of 46months (mo). Kaplan Meir survival analysis with log-rank Mantel Cox test, Cox proportional hazard was used, p<0.05 was considered significant.
Results
De-novo APML (n=89) patients had overall survival (OS) of 110.25 mo (95% CI 97.8-122.5) and early mortality rate of 10.1%. Of the treated patients (n=88), patients received ATRA-IDA (n=21), ATRA-IDA-ATO (n=30), ATRA-ATO (n=35), 7+3 Idarubicin/Cytarabine/ATRA (n=2). Event free survival, OS of patients on ATRA-IDA, ATRA-IDA-ATO, ATRA-ATO was 57.2%, 86.6 % and 88.5 % (p=0.0154); 80.3 (95% CI 55.5-105.1), 123 (95%CI 107-138.9) and 80.6 (95% CI 71.3-89.9) mo (p=0.041) respectively. Secondary malignancy occurred in 4.7%, 10%, 0% patients on ATRA-IDA, ATRA-IDA-ATO, ATRA-ATO respectively. Using Cox regression, age at diagnosis significantly influenced overall survival outcomes (p=0.01, HR 1.051 (95% CI 1.011-1.093).
Conclusion
Population-based outcomes of APML have shown an improvement in EFS and OS with ATRA-ATO which may be attributed to reduction in relapse-related mortality and secondary malignancies.
Keyword(s):
Abstract: PB1393
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Outcomes of Acute Promyelocytic Leukemia (APML) have improved considerably with the use of targeted therapies in trials.
Aims
We aimed to study the outcomes of APML in real-word WA patients.
Methods
Retrospective, multicentre analysis of survival outcomes of patients with APML presenting to public tertiary hospitals from 2005-2019 was undertaken, median follow-up of 46months (mo). Kaplan Meir survival analysis with log-rank Mantel Cox test, Cox proportional hazard was used, p<0.05 was considered significant.
Results
De-novo APML (n=89) patients had overall survival (OS) of 110.25 mo (95% CI 97.8-122.5) and early mortality rate of 10.1%. Of the treated patients (n=88), patients received ATRA-IDA (n=21), ATRA-IDA-ATO (n=30), ATRA-ATO (n=35), 7+3 Idarubicin/Cytarabine/ATRA (n=2). Event free survival, OS of patients on ATRA-IDA, ATRA-IDA-ATO, ATRA-ATO was 57.2%, 86.6 % and 88.5 % (p=0.0154); 80.3 (95% CI 55.5-105.1), 123 (95%CI 107-138.9) and 80.6 (95% CI 71.3-89.9) mo (p=0.041) respectively. Secondary malignancy occurred in 4.7%, 10%, 0% patients on ATRA-IDA, ATRA-IDA-ATO, ATRA-ATO respectively. Using Cox regression, age at diagnosis significantly influenced overall survival outcomes (p=0.01, HR 1.051 (95% CI 1.011-1.093).
Conclusion
Population-based outcomes of APML have shown an improvement in EFS and OS with ATRA-ATO which may be attributed to reduction in relapse-related mortality and secondary malignancies.
Keyword(s):